Trials / Completed
CompletedNCT02694978
A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,014 (actual)
- Sponsor
- AMAG Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety of 1.020 grams (g) of intravenous (IV) ferumoxytol compared to 1.500 g of IV ferric carboxymaltose (FCM).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ferumoxytol | |
| DRUG | FCM |
Timeline
- Start date
- 2016-02-29
- Primary completion
- 2017-01-16
- Completion
- 2017-07-17
- First posted
- 2016-03-01
- Last updated
- 2023-07-25
- Results posted
- 2018-06-11
Locations
127 sites across 7 countries: United States, Canada, Hungary, Latvia, Lithuania, Poland, Puerto Rico
Source: ClinicalTrials.gov record NCT02694978. Inclusion in this directory is not an endorsement.